Coverage
-
January 28, 2026
A New Jersey federal judge has given final approval to a $7.5 million settlement to end claims that AMAG Pharmaceuticals Inc. knew its preterm-birth prevention drug Makena was ineffective when it first marketed it, along with $2.5 million to class counsel in attorney fees.
3 other articles on this case.
View all »